Other · developed by Citius Pharmaceuticals
CITI-002 is a combination cream containing lidocaine and HBP, studied in patients with hemorrhoids.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05348200 | Phase 2 | Hemorrhoids | Completed | CTOR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hemorrhoids
Updated Nov 8, 2026. Something wrong or missing? Report it on the CTOR page.
See CTOR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTOR catalysts and pipeline →